| Nov 11 |
Sonoma Pharmaceuticals Receives New FDA 510(k) Clearance for Microcyn(R)-based Wound Care Hydrogel
|
| Nov 9 |
Sonoma Pharmaceuticals Second Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag
|
| Nov 8 |
Sonoma Pharmaceuticals GAAP EPS of -$0.59, revenue of $3.6M
|
| Nov 7 |
Sonoma Pharmaceuticals Reports Second Fiscal Quarter 2025 Financial Results
|
| Oct 31 |
Sonoma Pharmaceuticals to Exhibit at MEDICA 2024 in Düsseldorf
|
| Oct 22 |
Sonoma Pharmaceuticals Announces Expanded Partnership with Global Healthcare Distributor for Distribution of Wound Care Products in Canada
|
| Oct 21 |
Sonoma Pharmaceuticals to Present at Danisavage Financial Strategies, and LD Micro Main Event XVII Investor Conferences
|
| Sep 19 |
Sonoma Pharmaceuticals regains compliance with Nasdaq minimum bid price rule
|
| Sep 19 |
Sonoma Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Rule
|
| Sep 17 |
Sonoma Pharmaceuticals Receives New FDA 510(k) Clearance with Expanded Indications for Over-the-Counter Microcyn(R)-Based Solution
|
